ArticleMolecular biology reports2025
The impact of TMPRSS11A rs353163 and rs977728 polymorphisms on COVID-19 severity: genotypic and clinical associations.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveCOVID-19, caused by SARS-CoV-2, represents a significant global health challenge, with genetic factors influencing the severity of the disease. Transmembrane Serine Protease 11 A (TMPRSS11A) is a serine protease, and the relationship between the rs353163 and rs977728 polymorphisms in its coding region and COVID-19 severity has not been fully elucidated. In this context, we aimed to investigate the association between the TMPRSS11A rs353163 and rs977728 polymorphisms and the severity of COVID-19.
methodsThe study included 84 control participants, 80 patients with mild COVID-19 (MC-19), and 168 patients with severe COVID-19 (SC-19). Genotyping was conducted using the restriction fragment length polymorphism (RFLP) method. The genotype distributions, haplotype frequencies, and their relationships with clinical parameters were statistically analyzed.
resultsThis study investigated the impact of TMPRSS11A rs977728 C > T and rs353163 T > C polymorphisms on COVID-19 disease severity by examining their associations with genetic variations and clinical parameters. No homozygous mutant genotype was detected for the rs353163 T > C polymorphism. The heterozygous TC genotype was associated with a 3-fold increased risk of developing severe COVID-19 (OR = 3.300; p < 0.001). For the rs977728 C > T polymorphism, the TT and CT genotypes were observed at significantly higher frequencies in the SC‑19 group, corresponding to 7.6-fold and 2.3-fold increased risks, respectively. Haplotype analysis revealed that the rs977728 wild-type C / rs353163 mutant C* haplotype was strongly associated with SC‑19 disease severity. All genotype combinations carrying the mutant allele (rs977728 C > T / rs353163 T > C*) were associated with poor prognosis, as indicated by clinical parameters including CRP, D-dimer, ferritin, hs‑troponin, Neu, Neu%, Lym, Lym%, and Neu/Lym. ROC curve analysis identified CRP and D-dimer levels as sensitive markers for distinguishing the SC-19 group from other groups. Notably, the TT/TC* and CT/TC* genotype combinations were particularly associated with elevated CRP and D-dimer levels within the SC-19 group.
conclusionCarriers of the mutant alleles of TMPRSS11A rs977728 and rs353163 are thought to increase the risk of severe COVID‑19, in association with systemic inflammation, hypercoagulability, and organ damage.
Indexed as
Identifiers
41191166What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.